[ad_1] Wall Street analysts revealed bold predictions on four portfolio stocks this week, as investors digested the latest inflation data and December earnings season kicked off. Here’s a summary of each report, along with the Club’s updated take on each. Morgan Stanley Wall Street’s take: HSBC cut Morgan Stanley’s rating …
Read More »Tag Archives: stock takes
Walgreens and 3 other health-care stocks are going into our Bullpen watch list
[ad_1] We’re making our first Bullpen update of 2024. The Bullpen is a collection of stocks identified by the CNBC Investing Club team as having the potential to join Jim Cramer’s Charitable Trust. We’re highlighting the four most interesting investment opportunities we found out of the handful of company CEOs …
Read More »Obesity and Alzheimer’s drugs pack one-two punch to power Eli Lilly higher in 2024
[ad_1] Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors …
Read More »Prescriptions for Eli Lilly’s new weight-loss drug get off to a strong start and confirm bright outlook
[ad_1] The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according …
Read More »Weight gain after stopping Eli Lilly’s new obesity treatment should help, not hurt the stock
[ad_1] Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to us: It’s no reason to sell. Eli Lilly shares on Tuesday shook off afternoon losses to close higher by …
Read More »Flying solo without Cigna will keep Humana focused on 2 big priorities in the year ahead
[ad_1] It looks like Cigna has scrapped its takeover bid for Club holding Humana , removing a dark cloud over both stocks that’s lingered since the acquisition talks surfaced nearly two weeks ago. Cigna and Humana were unable to agree on an acquisition price and other financial terms, The Wall …
Read More »Why Pfizer’s latest stumble in the obesity market is a boon for Eli Lilly
[ad_1] Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron, after …
Read More »Jim Cramer blasts the prospect of a Humana-Cigna deal — it could never be approved by regulators
[ad_1] Jim Cramer urged Humana (HUM) not to pursue a merger with rival health insurer Cigna (CI), questioning the merits of a potential business combination and the likelihood of it passing U.S. antitrust review. Cigna and Humana could reach an agreement on a stock-and-cash transaction by the end of the …
Read More »